- Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia — Recruiting • Phase I • Gastroenterology • NCT06451770.
- A new gene-editing treatment (VERVE-201) was tested in patients with severe high cholesterol to assess safety and whether it reduces cholesterol levels.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
VT-20101 is an Open-label, Phase 1b, Single-ascending dose study that will evaluate the safety of VERVE-201 administered to patients with Refractory Hyperlipidemia. VERVE-201 uses base-editing technology designed to inactivate the expression of the ANGPTL3 gene in the liver and lower circulating low-density lipoprotein cholesterol (LDL-C) and triglycerides. This study is designed to determine the safety and pharmacodynamic profile of VERVE-201 in this patient population. Conditions: Hypercholesterolemia, Hypertriglyceridemia, Refractory Hyperlipidemia Interventions: VERVE-201 Lead Sponsor: Verve Therapeutics, Inc. Planned Enrollment: 36 participants